ArticleMaterials today. Bio2025
A selective RCC1 inhibitor loaded in membrane-coated DNA nanocage for targeted suppression of TNBC progression.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomimetic hybrid membrane-coated nanoparticles loaded with rhein-iron complex enhance ferroptosis and immunotherapy for triple-negative breast cancer.Materials today. Bio · 2026Article
- RCC1 knockdown sensitizes drug-resistant colorectal cancer to 5-fluorouracil or doxorubicin by impairing DNA repair.Cancer drug resistance (Alhambra, Calif.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) exhibits high recurrence rate and worse prognosis because of lacking effective targeted therapy. In this study, RCC1 was found to be highly expressed in TNBC and contribute to poor prognosis by promoting tumor progression through activation of Notch1 signaling pathway, suggesting that RCC1 is a potential therapeutic target for TNBC. Subsequently, Euphorbiasteroid (Ebd) was identified as a potent small-molecule inhibitor of RCC1 protein by high-throughput screening and can significantly suppress TNBC tumor growth and metastasis. To overcome the poor bioavailability and off-target effects of Ebd, a biomimetic nanodrug delivery system (TPRDN) was developed. Ebd was encapsulated within tetrahedral DNA nanocages assembled from four DNA oligonucleotide chains. These DNA nanocages were then coated with hybrid membranes composed of TNBC cell, platelet, and red blood cell membranes. Additionally, a Nectin-4 targeting bicyclic peptide was functionalized on the hybrid membranes to improve targeting precision. The TPRDN system can significantly target TNBC tissues and circulating tumor cells, thereby enhancing the inhibitory effects of Ebd on TNBC growth and metastasis, highlighting a promising strategy for precise and effective treatment for TNBC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.